相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression
Amy P. N. Skubitz et al.
GYNECOLOGIC ONCOLOGY (2013)
Targeting a cornerstone of radiation resistance: Cancer stem cell
Coralie Moncharmont et al.
CANCER LETTERS (2012)
Clinical Trial of the Intratumoral Administration of Labeled DC Combined With Systemic Chemotherapy for Esophageal Cancer
Shinichi Fujiwara et al.
JOURNAL OF IMMUNOTHERAPY (2012)
A Phase II Study of Oportuzumab Monatox: An Immunotoxin Therapy for Patients with Noninvasive Urothelial Carcinoma In Situ Previously Treated with Bacillus Calmette-Guerin
Mark Kowalski et al.
JOURNAL OF UROLOGY (2012)
EpCAM and its potential role in tumor-initiating cells
Sannia Imrich et al.
CELL ADHESION & MIGRATION (2012)
Regulation of CD133 by HDAC6 Promotes β-Catenin Signaling to Suppress Cancer Cell Differentiation
Anthony B. Mak et al.
CELL REPORTS (2012)
A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature
Alexander K. Tsai et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Targeting Tumor-Initiating Cancer Cells with dCD133KDEL Shows Impressive Tumor Reductions in a Xenotransplant Model of Human Head and Neck Cancer
Nate N. Waldron et al.
MOLECULAR CANCER THERAPEUTICS (2011)
CD133 suppresses neuroblastoma cell differentiation via signal pathway modification
H. Takenobu et al.
ONCOGENE (2011)
Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations
S. Floor et al.
ONCOGENE (2011)
EpCAM in carcinogenesis: the good, the bad or the ugly
Bernardina T. F. van der Gun et al.
CARCINOGENESIS (2010)
Targeting Wnt Signaling: Can We Safely Eradicate Cancer Stem Cells?
Fumi Takahashi-Yanaga et al.
CLINICAL CANCER RESEARCH (2010)
Multicellular tumor spheroids: An underestimated tool is catching up again
Franziska Hirschhaeuser et al.
JOURNAL OF BIOTECHNOLOGY (2010)
Bioengineering a Unique Deimmunized Bispecific Targeted Toxin That Simultaneously Recognizes Human CD22 and CD19 Receptors in a Mouse Model of B-Cell Metastases
Daniel A. Vallera et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Therapeutic implications of colon cancer stem cells
Eros Fabrizi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2010)
Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity
B. J. Stish et al.
BRITISH JOURNAL OF CANCER (2009)
Chemoresistant Colorectal Cancer Cells, the Cancer Stem Cell Phenotype, and Increased Sensitivity to Insulin-like Growth Factor-I Receptor Inhibition
Nikolaos A. Dallas et al.
CANCER RESEARCH (2009)
The Emerging Role of EpCAM in Cancer and Stem Cell Signaling
Markus Munz et al.
CANCER RESEARCH (2009)
Targeting CD133 antigen in cancer
Gabriella Ferrandina et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2009)
EpCAM-Positive Hepatocellular Carcinoma Cells Are Tumor-Initiating Cells With Stem/Progenitor Cell Features
Taro Yamashita et al.
GASTROENTEROLOGY (2009)
Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy
Daniel A. Vallera et al.
LEUKEMIA RESEARCH (2009)
Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis
Christine E. Eyler et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Cancer stem cells: A step toward the cure
Bruce M. Boman et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Tyrosine-kinase inhibition results in EGFR clustering at focal adhesions and consequent exocytosis in uPAR down-regulated cells of Head and Neck cancers
Samah Abu-Ali et al.
MOLECULAR CANCER (2008)
Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy
Scott J. Dylla et al.
PLOS ONE (2008)
An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes
Masanori Onda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The Stem Cell-Associated Antigen CD133 (Prominin-1) Is a Molecular Therapeutic Target for Metastatic Melanoma
Germana Rappa et al.
STEM CELLS (2008)
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
Jane E. Visvader et al.
NATURE REVIEWS CANCER (2008)
Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts
Raffit Hassan et al.
CLINICAL CANCER RESEARCH (2007)
Epithelial cell adhesion molecule - More than a carcinoma marker and adhesion molecule
Monika Trzpis et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv
Brad J. Stish et al.
CLINICAL CANCER RESEARCH (2007)
Epigenetic events of disease progression in head and neck squamous cell carcinoma
Maria J. Worsham et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2006)
Generation of CD133 + cells from CD133- peripheral blood mononuclear cells and their properties
EJ Suuronen et al.
CARDIOVASCULAR RESEARCH (2006)
Identification of a novel subpopulation of human cord blood CD34- CD133- CD7- CD45+lineage- cells capable of lymphoid/NK cell differentiation after in vitro exposure to IL-15
S Rutella et al.
JOURNAL OF IMMUNOLOGY (2003)
分享论文
